FDA Approves LEVORPHANOL TARTRATE — ACERTIS PHARMACEUTICALS, LLC

ACERTIS PHARMACEUTICS announced Friday that FDA approval of its generic version of oral levorphanol tartrate could expose the company to volume-dependent sales and delayed competitive launches by larger manufacturers. The authorization provides a near-term catalyst as the firm seeks to penetrate the unbranded market before biosimilar and established generic competition intensifies.